Latest & greatest articles for venlafaxine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on venlafaxine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on venlafaxine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for venlafaxine

41. A cost-effectiveness model of escitalopram, citalopram, and venlafaxine as first-line treatment for major depressive disorder in Belgium

A cost-effectiveness model of escitalopram, citalopram, and venlafaxine as first-line treatment for major depressive disorder in Belgium A cost-effectiveness model of escitalopram, citalopram, and venlafaxine as first-line treatment for major depressive disorder in Belgium A cost-effectiveness model of escitalopram, citalopram, and venlafaxine as first-line treatment for major depressive disorder in Belgium Demyttenaere K, Hemels M E, Hudry J, Annemans L Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The health technologies compared were escitalopram (10 - 20 mg/day), citalopram (20 - 40 mg/day) and venlafaxine (75 - 150 mg/day) as first-line treatment for major depressive disorder (MDD). MDD was defined as baseline

2005 NHS Economic Evaluation Database.

42. Cost effectiveness of duloxetine compared with venlafaxine-XR in the treatment of major depressive disorder

Cost effectiveness of duloxetine compared with venlafaxine-XR in the treatment of major depressive disorder Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 NHS Economic Evaluation Database.

43. Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: a meta-analysis of randomized clinical trials

Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: a meta-analysis of randomized clinical trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 DARE.

44. Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder

Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major (...) depressive disorder Trivedi M H, Wan G J, Mallick R, Chen J L, Casciano R, Geissler E C, Panish J M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Venlafaxine extended release (VXR) was compared with selective serotonin reuptake

2004 NHS Economic Evaluation Database.

45. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis

Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis Smith D, Dempster C, Glanville J, Freemantle N, Anderson I Authors' objectives (...) To investigate the relative efficacy and tolerability of venlafaxine compared with other antidepressants. Searching Relevant trials were identified from the authors' existing database (see Other Publications of Related interest no.1). In addition, the following databases were searched: MEDLINE, EMBASE, BIOSIS Previews, PsycLIT, the National Research Register, HealthSTAR, SIGLE, the Cochrane Controlled Trials Register and the Current Controlled Trials Register. The keywords were 'venlafaxine', 'efexor

2002 DARE.

46. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. (PubMed)

Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Hot flashes can be troublesome, especially when hormonal therapy is contraindicated. Preliminary data have suggested that newer antidepressants, such as venlafaxine, can diminish hot flashes. We undertook a double-blind, placebo-controlled, randomised trial to assess the efficacy of venlafaxine in women with a history of breast cancer or reluctance to take hormonal treatment because of fear (...) of breast cancer.Participants were assigned placebo (n=56) or venlafaxine 37.5 mg daily (n=56), 75 mg daily (n=55), or 150 mg daily (n=54). After a baseline assessment week, patients took the study medication for 4 weeks. All venlafaxine treatment started at 37.5 mg daily and gradually increased in the 75 mg and 150 mg groups. Patients completed daily hot-flash questionnaire diaries. The primary endpoint was average daily hot-flash activity (number of flashes and a score combining number and severity

2000 Lancet

47. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. (PubMed)

Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. Generalized anxiety disorder (GAD) is a chronic disorder that is associated with debilitating psychic and somatic symptoms. Venlafaxine extended-release (XR) capsules have been shown to be effective in short-term treatment of patients with GAD without major depressive disorder (MDD), but long-term data are needed to establish whether this agent (...) confers persistent benefits.To compare the 6-month efficacy and safety of a flexible dosage of venlafaxine XR in outpatients with GAD without associated MDD.Six-month, randomized, double-blind, placebo-controlled, parallel-group trial conducted May 1996 to October 1997.Fourteen outpatient clinics and private psychiatric practices in the United States.A total of 251 outpatients aged 18 years or older who met Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for GAD

2000 JAMA

48. Pharmacoeconomic analysis of venlafaxine in the treatment of major depressive disorder

Pharmacoeconomic analysis of venlafaxine in the treatment of major depressive disorder Pharmacoeconomic analysis of venlafaxine in the treatment of major depressive disorder Pharmacoeconomic analysis of venlafaxine in the treatment of major depressive disorder Einarson T R, Addis A, Iskedjian M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions (...) followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Venlafaxine in the treatment of acute depressive disorders. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Patient characteristics are published elsewhere, with a meta-analysis of effectiveness data. Setting Inpatient and outpatient settings were included. The economic analysis was carried out in Ontario, Canada. Dates to which data

1997 NHS Economic Evaluation Database.